GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 98.22 billion. The enterprise value is 111.58 billion.
Market Cap | 98.22B |
Enterprise Value | 111.58B |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 77.22 million shares outstanding. The number of shares has increased by 14.76% in one year.
Current Share Class | 77.22M |
Shares Outstanding | 77.22M |
Shares Change (YoY) | +14.76% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 51.53M |
Valuation Ratios
The trailing PE ratio is 1,724.17.
PE Ratio | 1,724.17 |
Forward PE | n/a |
PS Ratio | 3.34 |
PB Ratio | 4.97 |
P/TBV Ratio | 5.38 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 61.26, with an EV/FCF ratio of -20.99.
EV / Earnings | 1,958.81 |
EV / Sales | 3.79 |
EV / EBITDA | 61.26 |
EV / EBIT | 220.27 |
EV / FCF | -20.99 |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.76.
Current Ratio | 1.33 |
Quick Ratio | 0.58 |
Debt / Equity | 0.76 |
Debt / EBITDA | 8.36 |
Debt / FCF | -2.84 |
Interest Coverage | 0.78 |
Financial Efficiency
Return on equity (ROE) is 0.29% and return on invested capital (ROIC) is 0.87%.
Return on Equity (ROE) | 0.29% |
Return on Assets (ROA) | 0.70% |
Return on Invested Capital (ROIC) | 0.87% |
Return on Capital Employed (ROCE) | 1.67% |
Revenue Per Employee | 892.27M |
Profits Per Employee | 1.73M |
Employee Count | 33 |
Asset Turnover | 0.67 |
Inventory Turnover | 1.89 |
Taxes
In the past 12 months, GL Pharm Tech has paid 5.43 million in taxes.
Income Tax | 5.43M |
Effective Tax Rate | 8.71% |
Stock Price Statistics
The stock price has increased by +0.09% in the last 52 weeks. The beta is 0.92, so GL Pharm Tech's price volatility has been similar to the market average.
Beta (5Y) | 0.92 |
52-Week Price Change | +0.09% |
50-Day Moving Average | 1,149.68 |
200-Day Moving Average | 1,112.66 |
Relative Strength Index (RSI) | 67.78 |
Average Volume (20 Days) | 360,733 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 29.44 billion and earned 56.97 million in profits. Earnings per share was 0.74.
Revenue | 29.44B |
Gross Profit | 13.19B |
Operating Income | 491.11M |
Pretax Income | 62.40M |
Net Income | 56.97M |
EBITDA | 1.81B |
EBIT | 491.11M |
Earnings Per Share (EPS) | 0.74 |
Balance Sheet
The company has 1.73 billion in cash and 15.09 billion in debt, giving a net cash position of -13.37 billion or -173.10 per share.
Cash & Cash Equivalents | 1.73B |
Total Debt | 15.09B |
Net Cash | -13.37B |
Net Cash Per Share | -173.10 |
Equity (Book Value) | 19.76B |
Book Value Per Share | 256.69 |
Working Capital | 4.70B |
Cash Flow
In the last 12 months, operating cash flow was -4.00 billion and capital expenditures -1.31 billion, giving a free cash flow of -5.32 billion.
Operating Cash Flow | -4.00B |
Capital Expenditures | -1.31B |
Free Cash Flow | -5.32B |
FCF Per Share | -68.86 |
Margins
Gross margin is 44.80%, with operating and profit margins of 1.67% and 0.19%.
Gross Margin | 44.80% |
Operating Margin | 1.67% |
Pretax Margin | 0.21% |
Profit Margin | 0.19% |
EBITDA Margin | 6.13% |
EBIT Margin | 1.67% |
FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.76% |
Shareholder Yield | n/a |
Earnings Yield | 0.06% |
FCF Yield | -5.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 2.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.22 |
Piotroski F-Score | 4 |